Successful use of emicizumab prophylaxis in a patient with von Willebrand disease type 3: A case report
Journal of Hematology and Allied Sciences · 28.04.2026 · 6 · 173-176
DOI: 10.25259/jhas_56_2025 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Hematology and Allied Sciences, online erschienen am 28.04.2026. Verfasst von Himani Dendor und 3 weiteren Autor:innen. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
Von Willebrand disease (VWD) type 3 is the most severe form of VWD and is often inadequately controlled with plasma-derived von Willebrand factor (VWF)/FVIII or fresh frozen plasma. Emicizumab, a factor VIII– mimetic antibody approved for hemophilia A, enhances secondary hemostasis and has emerging off-label evidence in severe VWD. A 38-year-old woman with VWD type 3 and recurrent mucocutaneous bleeding despite regular factor therapy was started on emicizumab prophylaxis. Over 6 months, she remained bleed-free without additional factor support. Activated partial thromboplastin time normalized with increased measured FVIII activity; the apparent VWF antigen rise was interpreted cautiously. The treatment was well-tolerated and cost-effective. Emicizumab may offer an effective alternative prophylaxis in selected patients with severe VWD.
Zitieren
APA
Dendor, H., Suman, R. L., Yadav, M. K., & Damor, J. (2026). Successful use of emicizumab prophylaxis in a patient with von Willebrand disease type 3: A case report. Journal of Hematology and Allied Sciences, 6, 173-176. https://doi.org/10.25259/jhas_56_2025
Vancouver
Dendor H, Suman RL, Yadav MK, Damor J. Successful use of emicizumab prophylaxis in a patient with von Willebrand disease type 3: A case report. Journal of Hematology and Allied Sciences. 2026;6:173-176. doi:10.25259/jhas_56_2025
BibTeX
@article{Dendor2026,
author = {Dendor, Himani and Suman, Rameshwar Lal and Yadav, Mahendra Kumar and Damor, Jignesh},
title = {Successful use of emicizumab prophylaxis in a patient with von Willebrand disease type 3: A case report},
journal = {Journal of Hematology and Allied Sciences},
year = {2026},
volume = {6},
pages = {173--176},
doi = {10.25259/jhas_56_2025}
}
EUVIMED